Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 28 AUGUST 2026 ASX RELEASE RESULTS OF ANNUAL GENERAL MEETING Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to confirm that each of the resolutions put to its Annual General Meeting held earlier today were carried. Details of the results of the meeting are attached. This ASX announcement was approved and authorised for release by the Company Secretary. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 411 235 692 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of FAK, a protein over-expressed in multiple cancers and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in the ACCENT trial in advanced pancreatic cancer where it is dosed in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane® ) in first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy mFOLFIRINOX in advanced pancreatic cancer patients, and a third trial in ovarian cancer (the PRROSE trial) is scheduled to begin recruiting later this year. Resolution Result Resolution Resolution Type For Against Proxy's Discretion Abstain For Abstain* Carried / Not Carried 126,375,475 349,736 804,422 1,700 128,044,955 1,700 Carried 99.10% 0.27% 0.63% 99.73% 138,658,888 32,421 539,722 6,136,864 140,063,668 6,136,864 Carried 99.59% 0.02% 0.39% 99.98% 144,708,232 114,241 539,722 5,700 146,113,012 5,700 Carried 99.55% 0.08% 0.37% 99.92% 112,106,202 32,704,132 514,722 42,839 113,485,982 42,839 Carried 77.14% 22.50% 0.36% 77.63% 125,942,426 782,485 514,722 13,848,688 127,254,636 13,848,688 Carried 98.98% 0.61% 0.41% 99.34% 132,204,147 745,928 514,722 11,903,098 133,583,927 11,903,098 Carried 99.05% 0.56% 0.39% 99.44% 133,368,072 1,194,877 514,722 10,287,524 134,747,852 10,287,524 Carried 98.74% 0.88% 0.38% 99.12% 127,236,908 1,194,877 514,722 16,418,688 128,616,688 16,418,688 Carried 98.67% 0.93% 0.40% 99.08% 132,814,263 1,194,877 1,068,531 10,287,524 134,747,852 10,287,524 Carried 98.33% 0.88% 0.79% 99.12% 133,385,572 1,177,377 514,722 10,287,524 134,765,352 10,287,524 Carried 98.75% 0.87% 0.38% 99.13% AMPLIA THERAPEUTICS LIMITED Annual General Meeting Friday, 28 August 2026 Results of Meeting The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution details Instructions given to validly appointed proxies Number of votes cast on the poll (as at proxy close) (where applicable) Against 1 Remuneration Report Ordinary 349,736 0.27% 2 Re-elect Dr Robert Peach as a Director of the Company Ordinary 32,421 0.02% 3 Elect Mr Brett Carter as a Director of the Company Ordinary 114,241 0.08% 4 Approval for extra 10% Placement Facility Special 32,704,132 22.37% 5 Increase in Non-Executive Directors’ Fee Pool Special 850,055 0.66% 6 Proposed Issue of Zero Exercise Price Options to Dr Christopher Burns (Managing Director and Chief Executive Officer) Ordinary 745,928 0.56% 7 Proposed Issue of Zero Exercise Price Options to Ms Jane Bell (Non Executive Chair) Ordinary 1,194,877 0.88% 8 Proposed Issue of Zero Exercise Price Options to Dr Robert Peach (Non Executive Director) Ordinary 1,194,877 0.92% 9 Proposed Issue of Zero Exercise Price Options to Dr Warwick Tong (Non Executive Director) Ordinary 1,194,877 0.88% 10 Proposed Issue of Zero Exercise Price Options to Mr Brett Carter (Non Executive Director) Ordinary 1,177,377 0.87% * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. 1/1